Molecular determinants of vaccine-induced antibody durability

University Of Maryland Baltimore, Baltimore MD

Investigators

Abstract

This involves a clinical trial with vaccine-naïve volunteers using the licensed HPV vaccine, GARDASIL 9, for long-term responses, and an investigational HIV vaccine, GT1.1, for short-lived responses. Aim 1- A clinical trial will be carried out by vaccinating healthy volunteers intramuscularly with the HPV vaccine on the right thigh and GT1.1 on the left thigh, three times at 0, 1, and 6 months with scheduled collections of peripheral blood, lymph node fine needle aspirations (FNA), and bone marrow for 42 months to generate specimens spanning all phases of circulating antibody dynamics. Aim 2- The goal of Aim 2 is to quantify and characterize B cell responses the HPV capsid protein and gp120 epitopes in GT1.1 over the course of the clinical trial described above in the following specimens: